Comparative study of different glycating agents on human plasma and vascular cells

  • Rashmi S. TupeEmail author
  • Nilima Bangar
  • Arundhati Diwan
  • Dhanashri Changale
  • Shivani Choudhary
  • Shubhangi Chaware
Original Article


Diabetic complications are associated with the glycation and formation of advanced glycation end products (AGEs) which leads to structural modifications of biomolecules further affecting cells. Carbonyl compounds such as methylglyoxal and glyceraldehyde-3-phosphate are highly reactive and form an elevated amount of AGEs as compared to glucose and fructose. The investigation of glycation modifications by different compounds may be important to assess the specific pattern of biomolecular and cellular modifications and compare their glycation potential. The present work aims to comprehensively and comparatively examine the effect of glycating agents (glucose, fructose, ribose, methylglyoxal, and glyceraldehyde) on plasma, erythrocytes, platelets, and blood DNA. Glycation of plasma, cells, and DNA was initiated by incubating them with glycating agents for 24–48 h at 37 °C. Negative control samples (without glycating agents) were maintained simultaneously. After treatment, plasma and DNA samples were dialyzed and cell lysate was prepared. Markers of glycation (fructosamine), structural modifications (free amino, β-amyloid, absorption spectra), antioxidant indices (catalase activity, glutathione) and erythrocyte hemolysis were estimated. In the presence of glycating agents, there was a significant increase in the formation of fructosamine, structural modification markers and depletion in antioxidant indices. Overall results suggest that among all glycating agents; methylglyoxal and glyceraldehyde have more potency of glycation induced structural modifications in plasma and vascular cells. This indicates the specific glycation modifications in plasma and vascular cells by various glycating agents may be investigated further for controlling diabetic pathological changes.


Glycation Erythrocytes Platelets DNA Plasma 





(2,2-Azobis (2-amidinopropane) hydrochloride


Advanced glycation end products


Dimethyl sulfoxide


5, 5′-Dithiobis (2-nitrobenzoic acid)


Ethylenediaminetetraacetic acid






Nitro-blue tetrazolium


Phosphate buffer saline


Reactive oxygen species


Trichloroacetic acid


Radioimmunoprecipitation assay


White blood cells


N2-(1, R/S-carboxyethyl)-deoxyguanosine



We greatly acknowledge all the participants who volunteered in this study and Bharati Vidyapeeth Hospital for providing samples.

Compliance with ethical standards

Conflict of interest

The author declares that they have no conflict of interest.


  1. 1.
    Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefGoogle Scholar
  2. 2.
    Yamagishi S, Matsui T (2010) Advanced glycation end products, oxidative stress, and diabetic nephropathy. Oxid Med Cell Longev 3:101–108PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Baker JR, Metcalf PA, Johnson RN, Newman D, Rietz P (1985) Use of protein-based standards in automated colorimetric determinations of fructosamine in serum. Clin Chem 31:1550–1554PubMedPubMedCentralGoogle Scholar
  4. 4.
    Hsieh CL, Yang MH, Chyau CC, Chiu CH, Wang HE, Lin YC, Chiu WT, Peng RY (2007) Kinetic analysis of the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system. Biosystems 88:92–100PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Baynes JW (2002) The maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci 959:360–367PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Lapolla A, Traldi P, Fedele D (2005) Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 38:103–115PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Monnier VM, Nagaraj RH, Portero-Otin M, Glomb M, Elgawish AH, Sell DR, Friedlander MA (1996) Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant 11:20–26PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 47:24–27CrossRefGoogle Scholar
  9. 9.
    Wolff SP, Dean RT (1987) Glucose autoxidation, and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochem J 245:243–250PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Dhar A, Desai K, Kazachmov M, Yu P, Wu L (2008) Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism 57:1211–1220PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Nowotny K, Jung T, Hohn A, Weber D, Grune T (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5:194–222PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Frau J, Glossman-Mitnik D (2017) A conceptual DFT study of the molecular properties of the glycating carbonyl compound. Chem Cent J 11:8PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Phillips SA, Thornalley PJ (1993) The formation of methylglyoxal from triose phosphates an investigation using a specific assay for methylglyoxal. Eur J Biochem 212:101–105PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Dutta U, Cohenford MA, Dain JA (2006) Monitoring the effect of glucosamine and glyceraldehyde glycation on the secondary structure of human serum albumin and immunoglobulin G: an analysis based on circular dichroism, thermal melting profiles, and UV–fluorescence spectroscopy. Anal Biochem Acta 558:187–194CrossRefGoogle Scholar
  16. 16.
    Ulrich P, Cerami A (2001) Protein glycation, diabetes, and aging. Recent Prog Horm Res 56:1–21PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Wautier JL, Guillausseau PJ (1998) Diabetes, advanced glycation endproducts and vascular disease. Vasc Med 3:131–137PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Adeshara KA, Diwan AG, Jagtap TR, Advani K, Siddiqui A, Tupe RS (2017) The relationship between plasma glycation with membrane modification, oxidative stress and expression of glucose transporter-1 in type 2 diabetes patients with vascular complications. J Diabetes Complic 31(2):439–448CrossRefGoogle Scholar
  19. 19.
    Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J et al (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91(16):7742–7749PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Coban E, Bostan F, Ozdogan M (2006) The mean platelet volume in subjects with impaired fasting glucose. Platelets 17:67–76PubMedCrossRefGoogle Scholar
  21. 21.
    Rubenstein DA, Yin W (2009) Glycated albumin modulates platelet susceptibility to flow-induced activation and aggregation. Platelets 20:206–215PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Stopper H, Schinzel R, Sebekova K, Heidland A (2003) Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 190:151–157PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Orie NN, Zidek W, Tepel M (1999) Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 12:1169–1174PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Mizutani K, Ikeda K, Nishikata T, Yamori Y (2000) Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Hypertens 18:1833–1840PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Pazdro R, Burgess JR (2012) Differential effects of α-tocopherol and N-acetyl-cysteine on advanced glycation end product induced oxidative damage and neurite degeneration in SH-SY5Y cells. Biochim Biophys Acta 1822:550–556PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Akhter F, Salman Khan M, Shahab U, Moinuddin Ahmad S (2013) Biophysical characterization of ribose induced glycation: a mechanistic study on DNA perturbations. Int J Biol Macromol 58:206–216PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Adeshara K, Tupe R (2016) Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes. Mol Biol Rep 43(3):195–205PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Sambrook JF, Russell DW (2001) Molecular cloning: a laboratory manual, vol 1–3, 3rd edn. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
  29. 29.
    Klunk WE, Jacob RF, Mason RP (1999) Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol 309:285–305PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Acimovic JM, Jovanovic VB, Veselinovic MR, Sreckovic VD, Mandic LM (2011) Method for monitoring of the protein amino group changes during carbonylation. Clin Biochem 44:994–999PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Baraka VJ, Navarra G, Leone M, Bourdon E, Militello V (1840) Rondeau P (2014) Deciphering metal-induced oxidative damages on glycated albumin structure and function. Biochim Biophys Acta 6:1712–1724Google Scholar
  32. 32.
    Ajilia CM, Prasada Rao UJ (2008) Protection against hydrogen peroxide induced oxidative damage in rat erythrocytes by Mangifera indica L. peel extract. Food Chem Toxicol 46:303–309CrossRefGoogle Scholar
  33. 33.
    Guerin-Dubourg A, Catan A, Bourdon E, Rondeau P (2012) Structural modifications of human albumin in diabetes. Diabetes Metab 38:171–178PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Aebi H (1984) Catalase in vitro. In: Packer L (ed) Methods enzymol, vol 105. Academic Press, New York, pp 121–126Google Scholar
  36. 36.
    Monnier VM, Genuth S, Sell DR (2016) The pecking order of skin advanced glycation endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in type 1 diabetes. Glycoconj J 33:569–579PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Sakurai T, Tsuchiya S (1988) Superoxide production from nonenzymatically glycated protein. FEBS Lett 236:406–410PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA (2008) Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Free Radic Biol Med 44:1276–1285PubMedCrossRefGoogle Scholar
  39. 39.
    Armbruster DA (1987) Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 33:2153–2163PubMedGoogle Scholar
  40. 40.
    Bouma B, Kroon-Batenburg LM, Wu YP et al (2003) Glycation induces the formation of amyloid cross-beta structure in albumin. J Biol Chem 278(43):41810–41819PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53:119–124CrossRefGoogle Scholar
  42. 42.
    Chelikani P, Fita I, Loewen PC (2004) Diversity of structures and properties among catalases. Cell Mol Life Sci 61(2):192–208PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Iberg N, Flückiger R (1986) Nonenzymatic glycosylation of albumin in vivo identification of multiple glycosylated sites. J Biol Chem 261:13542–13545PubMedPubMedCentralGoogle Scholar
  44. 44.
    Hasan NA (2009) Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. Saudi Med J 30:1263–1271PubMedPubMedCentralGoogle Scholar
  45. 45.
    Rubenstein DA, Yin W (2009) Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets 20:206–215PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Dunn EJ, Philippou H, Ariëns RA, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071–1080PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Waczulıkova I, Sikurova L, Carsky J, Strbova L, Krahulec B (2000) The decreased fluidity of isolated erythrocyte membranes in type 1 and type 2 diabetes the effect of resorcylidene aminoguanidine. Gen Physiol Biophys 19:381–392PubMedPubMedCentralGoogle Scholar
  48. 48.
    Kumar R (2012) Biochemical changes in erythrocyte membrane in type 2 diabetes mellitus. Indian J Med Sci 66:131–135PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Rodrigo R, Bächler JP, Araya J, Prat H, Passalacqua W (2007) Relationship between (Na + K)-ATPase activity, lipid peroxidation and fatty acid profile in erythrocytes of hypertensive and normotensive subjects. Mol Cell Biochem 303:73–81PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Reshamwala SM, Patil ND (2005) Biochemical changes in erythrocyte membrane in uncontrolled type2 diabetes mellitus. Indian J Biochem Biophys 42:250–253PubMedPubMedCentralGoogle Scholar
  51. 51.
    Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Thornalley PJ, Schleicher E, Wieder T, Lang F (2006) Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 18:223–232PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y (1998) Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 41(2):131–137PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Kasai K, Nakamura T et al (1983) Increased glycosylation of protein from cataractous lenses in diabetes. Diabetologia 25:36–44PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Hack N, Crawford N (1984) Two-dimensional polyacrylamide gel electrophoresis of the protein and glycoprotein of purified human platelet surface and intracellular membranes. Biochem J 222:235–246PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Jackson SP (2011) Arterial thrombosis–insidious, unpredictable and deadly. Nat Med 17:1423–1436PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Tang WH, Stitham J, Jin Y et al (2014) Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 129:1598–1609PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Lee SH, Du J, Stitham J et al (2016) Inducing mitophagy in diabetic platelets protects against severe oxidative stress. EMBO Mol Med 8:779–795PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Buczynski A, Wachowicz B et al (1993) Changes in antioxidant enzyme activities, aggregability and malonyldialdehyde concentration in blood platelets from patients with coronary heart disease. Atherosclerosis 100:223–228PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Kaur G, Pandey NR et al (2000) Lipid peroxidation in human blood platelets during unstable angina and myocardial infarction. Boll Chim Farm 139:267–269PubMedGoogle Scholar
  61. 61.
    Thornalley PJ (1999) The clinical significance of glycation. Clin Lab 45:263–273Google Scholar
  62. 62.
    Sengupta B, Uematsu T, Jacobsson P, Swenson J (2006) Exploring the antioxidant property of bioflavonoid quercetin in preventing DNA glycation: a calorimetric and spectroscopic study. Biochem Biophys Res Commun 339:355–361PubMedCrossRefGoogle Scholar
  63. 63.
    Thornalley PJ, Waris S, Fleming T et al (2010) Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumor multidrug resistance. Nucleic Acids Res 38:5432–5442PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Murata-Kamiya N, Kamiya H, Kaji H, Kasai H (1997) Glyoxal a major product of DNA oxidation, induces mutations at G: C sites on a shuttle vector plasmid replicated in mammalian cells. Nucleic Acids Res 25:1897–1902PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Westwood ME, Thornalley PJ (1995) Molecular characteristics of methylglyoxal-modified bovine and human serum albumins comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 14:359–372PubMedCrossRefGoogle Scholar
  66. 66.
    Wei Y, Chen L, Chen J, Ge L, He RQ (2009) Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell Biol 10:1471–2121CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Biochemical Sciences DivisionRajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth (Deemed to be University)PuneIndia
  2. 2.Department of MedicineBharati Vidyapeeth’s Medical College and Bharati Hospital, Bharati Vidyapeeth (Deemed to be University)PuneIndia

Personalised recommendations